![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24469-24474, August 27, 1999
§,
,
,
,
,
,
,
,
,
, and
From the
Section of Hematology-Oncology, University
of Illinois at Chicago and West Side Veterans Affairs Medical Center,
Chicago, Illinois 60607, the ¶ Department of Pharmacology, Medical
College of Virginia, Richmond, Virginia 23298, the
Terry Fox
Laboratory, British Columbia Cancer Research Centre, Vancouver, British
Columbia V5Z 1L3, Canada, the ** Lerner Research Institute, Cleveland
Clinic Foundation, Cleveland, Ohio 44195, and the

Division of Molecular Oncology, Biomedical
Research Center, Osaka University Graduate School of Medicine,
Osaka 565-0871, Japan
| |
ABSTRACT |
|---|
|
|
|---|
Several signaling cascades are activated during
engagement of the erythropoietin receptor to mediate the biological
effects of erythropoietin. The members of the insulin receptor
substrate (IRS) family of proteins play a central role in signaling for various growth factor receptors and cytokines by acting as docking proteins for the SH2 domains of signaling elements, linking cytokine receptors to diverse downstream pathways. In the present study we
provide evidence that the recently cloned IRS-related proteins, Gab1
and Gab2, of the Gab family of proteins, are rapidly phosphorylated on
tyrosine during erythropoietin treatment of erythropoietin-responsive cells and provide docking sites for the engagement of the SHP2 phosphatase and the p85 subunit of the phosphatidylinositol 3'-kinase. Furthermore, our data show that Gab1 is the primary IRS-related protein
activated by erythropoietin in primary erythroid progenitor cells. In
studies to identify the erythropoietin receptor domains required for
activation of Gab proteins, we found that tyrosines 425 and 367 in the
cytoplasmic domain of the erythropoietin receptor are required for the
phosphorylation of Gab2. Taken together, our data demonstrate that Gab
proteins are engaged in erythropoietin signaling to mediate downstream
activation of the SHP2 and phosphatidylinositol 3'-kinase pathways and
possibly participate in the generation of the erythropoietin-induced
mitogenic responses.
Erythropoietin (EPO)1 is
a glycoprotein hormone that acts as the principal regulator of
erythroid development. EPO plays a critical role in the regulation of
cell survival and proliferation of erythroid progenitors that are at
the burst-forming unit erythroid (BFU-E) and colony-forming
unit-erythroid (CFU-E) stages of development (1-4). Previous studies
have established that binding of EPO to its receptor results in
activation of multiple signaling pathways including the Jak/Stat,
Shc/Grb2/Ras, and the PI 3'-kinase signaling cascades (5-22),
suggesting that multiple pathways are activated and operate to mediate
the effects of EPO on target cells.
The members of the insulin receptor substrate (IRS)1 family
of SH2 docking proteins participate in signaling cascades activated by
various cytokines in hematopoietic cells (23-31). These proteins have
multiple tyrosine phosphorylation sites that act as docking sites for
the SH2 domains of various signaling proteins. These allow IRS proteins
to function as multisite docking proteins and link cytokine receptors
to multiple signaling pathways. Recently, two new members of the IRS
family have been identified and their cDNAs cloned, Gab1 and Gab2.
Gab1 shares amino acid and structural homology with IRS-1 and contains
multiple tyrosines that are putative binding sites for several
SH2-containing downstream signaling molecules (31). Recent studies have
demonstrated that Gab1 is involved in signaling via the epidermal
growth factor (31), insulin (31), nerve growth factor (32), IL-3,
IL-6/gp130 (32), TPO, T-cell, and B-cell receptors (33). Gab2 is also a
recently cloned member of this family that shares common features with Gab1 and IRS-1 (34, 35) and has been shown to participate in IL-2,
IL-3, IL-6, gp130, TPO, SCF, CSF-1, BCR, and TCR signaling (34, 35).
Both Gab1 and Gab2 contain multiple sites for tyrosine phosphorylation
and motifs for binding of SH2 and SH3 containing proteins. In addition,
both Gab1 and Gab2 contain a c-Met binding domain and are related to
the Drosophila homologue Daughter of Sevenless (DOS). The
greatest amino acid sequence identity within the Gab/DOS proteins are
found in their pleckstrin homology domains (34, 35). Although IRS
proteins have similar structure, they can be distinguished from Gab/DOS
proteins by their pleckstrin homology domains and other sequence
elements. Therefore, it is likely that, in addition to mediating the
activation of common pathways, Gab proteins have also distinct
signaling and biological functions as compared with other IRS proteins.
In the current study we determined whether members of the Gab family of
proteins are involved in EPO signaling in the EPO-dependent cell lines HCD57, DA3ER, and in highly purified human primary erythroid
progenitors. Our data demonstrate that EPO induces strong tyrosine
phosphorylation of Gab1 and Gab2, and that both Gab1 and Gab2 interact
with the p85 subunit of the PI 3'-kinase and the SHP2 phosphatase,
suggesting that their function is required for the engagement of these
proteins by the EPO receptor. In addition, our data show that the
proteins are differentially expressed in various cell lines, while only
Gab1 is expressed in primary hematopoietic progenitors. In studies with
DA3 cells expressing different EPO receptor mutants we identify
tyrosines 367 and 425 in the EPO receptor, as the sites required for
the engagement of the Gab pathway in EPO signaling.
Cell Culture and Reagents--
HCD57 cells were cultured in
Iscove's modified Dulbecco's medium (BioWhittaker Inc., Walkerville,
MD), 25% fetal calf serum, 10 µg/ml gentamicin, 1 unit of EPO/ml at
37 °C in a 5% CO2 environment. DA3ER and DA3ER mutant
cell lines were cultured in RPMI media, 10% fetal calf serum, 10 µg/ml gentamicin, 4 units of EPO/ml at 37 °C in a 5%
CO2 environment as described previously (18). All other
cell lines were maintained in RPMI media, 10% fetal calf serum, 10 µg/ml gentamicin at 37 °C in a 5% CO2 environment.
Human BFU-E were purified from peripheral blood obtained from normal
volunteers. Informed consent was obtained from the volunteers after
approval from the Institutional Review Board at the University of
Illinois at Chicago. The purified BFU-E cells were cultured for 7 or 8 days to obtain a highly enriched population of erythroid progenitors
that were at the CFU-E stage of differentiation as described previously
(4, 36). Briefly, 300 to 400 ml of whole blood was separated over
Ficoll-Hypaque (1.077 g/ml) to obtain mononuclear cells. Platelets were
depleted by centrifugation over a 10% bovine serum albumin gradient,
followed by adherent cell depletion in polystyrene tissue culture
flasks. The cell population was enriched for BFU-E by negative
selection with MACSTM antibody-coated paramagnetic
microbeads (Miltenyi Biotec, Inc., Auburn, CA) bearing CD3, CD11b,
CD15, and CD45 RA. Day 0 cells were then cultured for 7 days to obtain
highly purified erythroid progenitors at the CFU-E stage of
differentiation. Eighty to ninety percent of these cells were positive
for CD71 and glycophorin A as determined by flow cytometry and produced
erythroid colonies when plated in methylcellulose. The culture medium
contained 15% fetal calf serum, 15% human AB serum, Isocove's
modified Dulbecco's medium, 500 units/ml penicillin, 40 µg/ml
streptomycin/ml, 10 ng/ml interleukin-3, 2 units/ml EPO, 50 units/ml
insulin-like growth factor-1, 50 ng/ml stem cell factor. Hematopoietic
stem cell progenitors (CD34+ Lin Immunoprecipitations and Immunoblotting--
Prior to growth
factor stimulation, HCD57 cells were centrifuged and the cell pellets
were washed two times with Isocove's modified Dulbecco's medium and
cultured in Isocove's modified Dulbecco's medium, 25% fetal calf
serum without growth factors for 16-18 h. 30 × 106
cells were treated with 10 units/ml EPO or left untreated. DA3ER cells
and DA3ER mutants were also deprived of EPO for 16-18 h, and treated
with 50 units/ml EPO. Human primary erythroid progenitors were
stimulated on day 8 of culture. Prior to EPO stimulation, the human
erythroid progenitors cells were starved in serum-free medium without
growth factors for 4 h. 20 × 106 cells were
treated with 10 units/ml EPO or left untreated. Cells were lysed in a
phosphorylation lysis buffer containing 50 mM Hepes (pH
7.3), 150 mM sodium chloride, 1 mM EDTA, 1.5 mM magnesium chloride, 100 mM sodium fluoride,
10 mM sodium pyrophosphate, 200 µM sodium
orthovanadate, 10% glycerol, 0.5% Triton X-100, and 1 mM
phenylmethylsulfonyl fluoride. Cell lysates were immunoprecipitated with the indicated antibodies, and after five washes with
phosphorylation lysis buffer containing 0.1% Triton X-100, proteins
were analyzed by SDS-PAGE. The proteins were transferred onto
polyvinylidene difluoride filters (Immobilon), and the residual binding
sites on the filters were blocked by incubating with TBST (10 mM Tris, pH 8.0, 150 mM sodium chloride, 0.05%
Tween 20), 20% bovine serum albumin for 1-3 h at room temperature or
overnight at 4 °C. The filters were subsequently incubated with the
indicated antibodies and developed using the enhanced chemiluminescence
(ECL) kit following the manufacturer's recommended procedure (Amersham).
Polymerase Chain Reaction (PCR) Amplification--
PCR
amplification was performed on isolated RNA from various cell lines and
primary hematopoietic cells using a RNA Core Kit (Perkin Elmer, Foster
City, CA) according to the manufacturer's instructions. One microgram
of total RNA was used for cDNA synthesis using random hexamers for
first strand synthesis. The synthesized cDNA was equally divided
and used for PCR amplification of Gab1, Gab2, and glyceraldehyde
phosphate dehydrogenase (GAPDH). PCR amplification was performed with
specific forward and reverse primers for Gab1 (forward,
5'-CCTGTTGCTCATCAACTGTCAAAGC-3'; reverse, 5'-CTACA
CTCGATGTCCCAGATGGG-3') and Gab2 (forward, 5'-GCCACTCCTGGAGATTCAGCC- 3';
reverse, 5'-GTCAGGCTTGAGGTTTCGGTTG-3') using the following conditions: 1 cycle at 94 °C/2 min; 5 cycles at 94 °C/10 s,
65.5 °C/2 min; 5 cycles at 94 °C/10 s, 62.5 °C/2 min; 30 cycles at 94 °C/10 s, 62 °C/2 min, 72 °C/10 min. Control PCR
amplifications were performed using specific forward and reverse
primers for GAPDH (forward, 5'GGCTGAGAACGGGAAGCTTG TCAT-3' and reverse,
5'-CAGCCTTCTCCATGGTGGTGAAGA-3') using similar conditions.
In Vitro Kinase Assays--
Cell lysates were immunoprecipitated
with the indicated antibodies. In vitro kinase assays were
performed as described previously (37).
We initially sought to determine whether Gab1 and Gab2 are
tyrosine phosphorylated in response to EPO treatment of HCD57 cells. Cells were stimulated with EPO after starvation and cell lysates were
immunoprecipitated with anti-Gab1 or anti-Gab2 antibodies, followed by
SDS-PAGE analysis and immunoblotting with anti-phosphotyrosine. Tyrosine-phosphorylated proteins corresponding to Gab1 and Gab2 were observed after EPO stimulation in the anti-phosphotyrosine blots,
while there was no change in the amount of these proteins immunoprecipitated from lysates of EPO-treated and untreated cells (Fig. 1, A-D). In addition, a
tyrosylphosphoprotein migrating at approximately 72 kDa was
co-immunoprecipitated by both anti-Gab1 and anti-Gab2 antibodies after
EPO treatment of cells (Fig. 1, A and C). We
subsequently determined if IRS-1 and/or IRS-2 are tyrosine
phosphorylated by EPO in HCD57. We could not detect
EPO-dependent tyrosine phosphorylation of IRS-1, while
IRS-2 was heavily phosphorylated in the absence of EPO in these cells
and its phosphorylation status did not change after EPO treatment (Fig.
1E). Thus, in these cells, Gab1 and Gab2, but not IRS-1 or
IRS-2, appear to be the principal IRS proteins activated by EPO,
strongly suggesting that their phosphorylation is critical for the
generation of EPO- induced signals.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
population)
were isolated from adult bone marrow by flow cytometry after the
initial selection of CD34+ population by a CD34 selection
kit (Miltenyi Biotech, Auburn, CA). The lineage panel (Lin) consisted
of CD2, CD14, CD15, CD19, and glycophorin A. Anti-Gab1, anti-PI
3-kinase, IRS-2, and anti-Jak-2 antibodies were purchased from Upstate
Biotechnology, Inc. (Lake Placid, NY). The anti-Gab2 antibody has been
previously described (34). An anti-EPOR antibody was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). An anti-SHP2 antibody
was purchased from Transduction Laboratories. An antibody against IRS-1
was provided by Dr. Morris White (Joslin Diabetes Center, Boston, MA).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (41K):
[in a new window]
Fig. 1.
EPO induces tyrosine phosphorylation of Gab1
and Gab2. HCD57 cells were incubated for 5 min at 37 °C in the
presence or absence of EPO as indicated. Cell lysates were
immunoprecipitated with either nonimmune rabbit serum (NRS)
or a polyclonal antibody against Gab1 as indicated. The
immunoprecipitates were equally divided and immnoblotted with either:
A, anti-phosphotyrosine antibody; or B, an
anti-Gab1 antibody. C, HCD57 cells lysates were
immunoprecipitated with either NRS or a polyclonal antibody against
Gab2 as indicated and immunoblotted with anti-phosphotyrosine
(PTyr). D, the blot shown in C was
stripped and immunoblotted with an anti-Gab2 antibody. E,
HCD57 cells were stimulated with EPO as indicated. Cell lysates were
immunoprecipitated with NRS, anti-IRS-1, anti-IRS-2, or anti-Gab1
antibodies and immunoprecipitated proteins were analyzed by SDS-PAGE
and immunoblotted with an anti-phosphotyrosine antibody.
In studies to determine the kinetics of tyrosine phosphorylation of
Gab1, we found that its activation was rapid and transient, reaching a
maximum level of phosphorylation at 15 min, with the signal diminishing
after 30 min of EPO treatment. In addition, the Gab1-associated
72-kDa tyrosylphosphoprotein followed a similar time course of
phosphorylation (Fig. 2A).
|
We then sought to determine the expression pattern of Gab1 and Gab2
proteins in various hematopoietic cell lines and primary hematopoietic
cells (CD34+ Lin
) by RT-PCR. These cell lines
represented all the major hematopoietic lineages. The primary cells
that were utilized in the study consisted of highly purified human
early hematopoietic stem cell progenitors and highly purified human
erythroid progenitors that are at the CFU-E stage of differentiation.
Fig. 3 shows the expression pattern of
Gab1, Gab2, and GAPDH mRNA for each of the cell types utilized in
the study. Gab1 is clearly expressed in all the cell lines and in
primary hematopoietic progenitors although in the
EPO-dependent myeloid cell line DA3ER Gab1 expression is
absent. On the other hand, Gab2 mRNA expression was limited to
HCD57, DA3ER, and TF-1 cells. We were unable to detect the expression
of Gab2 transcripts in early human hematopoietic stem cell progenitors
and committed human erythroid progenitors at the CFU-E stage of
differentiation. The bands obtained for Gab1 (316bp) and Gab2(512bp)
were specific for cDNA (+RT) as no bands were detected in the
absence of reverse transcriptase (
RT) during the cDNA synthesis
step (Fig. 3). Control PCR amplification with primers to GAPDH
confirmed that the isolated RNA could be PCR amplified and the quantity
of RNA used was similar for all the tissues. Furthermore, DNA
sequencing of all positive reactions confirmed the amplification of
Gab1 and Gab2 transcripts from these cell types (data not shown).
|
Since RT-PCR experiments indicated that Gab1 was the only Gab
transcript that was detected in primary erythroid progenitors, we
sought to determine whether Gab1 is phosphorylated in response to EPO
treatment of highly purified human erythroid progenitors. Fig.
4 shows that Gab1 is phosphorylated in an
EPO-dependent manner and that such tyrosine phosphorylation
is rapid, reaching a maximum level of phosphorylation at 15 min, with
the signal diminishing after 30 min of EPO treatment. A second
unidentified protein that closely migrated with Gab1 was
co-immunoprecipitated with the anti-Gab1 antibody and was also
phosphorylated by EPO (Fig. 4). This was in addition to the
Gab1-associated 72-kDa tyrosylphosphoprotein that was seen in the
EPO-dependent cell lines (Fig. 4). Greater than 90% of the
cells studied were CD71/glycophorin A positive as determined by flow
cytometry (Fig. 4, bottom panel), indicating that they were
purified progenitors committed to the erythroid lineage.
|
We next sought to determine whether the p85 regulatory subunit of the
PI 3'-kinase interacts with Gab1 and/or Gab2 during EPO stimulation.
Fig. 5A shows an experiment in
which lysates from HCD57 cells were immunoprecipitated with an
anti-Gab1 antibody, followed by SDS-PAGE analysis and immunoblotting
with an antibody against the p85 regulatory subunit of PI 3'-kinase.
Association of p85 was detectable before EPO stimulation and increased
after EPO stimulation in an EPO-dependent manner, strongly
suggesting that the tyrosine-phosphorylated form of Gab1 provides
docking sites for the binding of the SH2 domains of PI 3'-kinase during EPO stimulation. However, as there was some constitutive association of
p85 with Gab1, it is possible that the SH3 domain of the PI 3'-kinase
or other p85-interacting proteins can associate with Gab1 and this
needs to be determined in future studies. To determine whether the
serine kinase activity of the PI 3'-kinase is induced during its
interaction with Gab1, in vitro kinase assays were performed
on anti-Gab1 immunoprecipitates. Fig. 5B shows that, after
EPO stimulation, kinase activity is clearly detectable in anti-Gab1
immunoprecipitates and a phosphorylated protein corresponding to p85 is
detected, strongly suggesting that the p110 catalytic subunit of PI
3'-kinase is activated during the association of p85 with Gab1. Fig.
5C shows an experiment in which lysates from HCD57 cells
were immunoprecipitated with an anti-Gab2 antibody, followed by
SDS-PAGE analysis and immunoblotting with an antibody against the p85
regulatory subunit of the PI 3'-kinase. There was some baseline
interaction between Gab2 and p85 detected. Such an interaction
increased significantly after treatment with Epo, suggesting that the
tyrosine-phosphorylated form of Gab2 also binds the SH2 domains of
P85 during Epo stimulation. Thus both members of the Gab family of
proteins provide docking sites for the engagement of PI 3'-kinase in
EPO-induced signaling.
|
We subsequently sought to identify the 72-kDa protein that was
phosphorylated and co-immunoprecipitated with Gab1 and Gab2 during EPO
stimulation. As the relative molecular mass (Mr)
of this protein was similar to the Mr of the EPO
receptor and the Mr of the SHP2 phosphatase, we
performed studies to determine if the EPO receptor or the SHP2
phosphatase can be detected in association with Gab1 during EPO
stimulation. HCD57 cells were stimulated with EPO for different times
and cell lysates were immunoprecipitated with antibodies against Gab1,
followed by SDS-PAGE analysis and immunoblotting with
anti-phosphotyrosine (Fig.
6A). The 72-kDa protein
co-migrated with the EPO receptor, but it was not recognized by an
antibody specific for the EPOR (Fig. 6A, middle panel).
However, when anti-SHP2 immunoblots were performed, we found that the
protein was recognized by an anti-SHP2 monoclonal antibody (Fig.
6A, bottom panel), establishing that it corresponds, at
least in part, to the SHP2 phosphatase. Thus, in addition to binding
the p85 regulatory subunit of the PI 3'-kinase, Gab1 interacts with the
SHP2 phosphatase, strongly suggesting that its docking function
recruits SHP2 in EPO signaling. Similarly, when anti-SHP2 immunoblots
were performed on anti-Gab2 immunoprecipitates from EPO-treated cells,
we found that SHP2 associates with Gab2 in an EPO-dependent
manner, suggesting that Gab2 also provides a binding site for SHP2
(Fig. 6B).
|
To identify the domains in the EPO receptor that are required for
EPO-dependent phosphorylation of Gab proteins, we
determined Gab2 phosphorylation in a series of DA3 cell line
transfectants, expressing different mutations of the EPO receptor. Each
of these mutants lacked one phosphotyrosine residue due to the
substitution of phenylalanine in place of tyrosine, with the exception
of the ERH mutant, which contained only the most proximal tyrosine
residue to the cytoplasm and lacked seven of the eight tyrosine
residues within the cytoplasmic domain of the erythropoietin receptor. Fig. 7 shows phosphotyrosine immunoblots
using five such mutant clones of DA3ER cells. Lysates from
EPO-stimulated cells of the different transfectants were
immunoprecipitated with Gab2 and Jak2 antibodies. The cells expressing
EPO receptors with mutated tyrosines 367 and 425 (Y367F and Y425F)
showed no phosphorylation of Gab2 in response to EPO, although there
was strong activation of Jak2, suggesting that these phosphotyrosine
residues are required for the activation of Gab2. Similarly, no
tyrosine phosphorylation of Gab2 was seen in cells expressing the ERH
mutant, in which seven of the eight tyrosines including tyrosines 367 and 425 were not present. However, in Y453F and Y467F expressing cells,
there was phosphorylation of Gab2, indicating that these
phosphotyrosine residues are not required for its activation. Thus
tyrosines 367 and 425 in the EPO receptor are required for engagement
of Gab2 in EPO signaling.
|
| |
DISCUSSION |
|---|
|
|
|---|
Gab1 and Gab2 are recently cloned members of the Gab family of proteins which are related to the IRS proteins (31). Many of the motifs present in IRS-1 are conserved in Gab1, including three tyrosines in YXXM motifs that provide docking sites for the p85 regulatory subunit of the PI 3'-kinase and a tyrosine in a YXDL motif that binds the SH2 domain of the SHP2 phosphatase. Recent studies have demonstrated that Gab1 and Gab2 are activated and engaged in signaling via the insulin, epidermal growth factor, nerve growth factor, IL-6, and other cytokine receptors (31-35), suggesting that the protein plays an important role in the generation of biological responses for various cytokines and growth factors.
Extensive previous studies have demonstrated that erythropoietin activates multiple signaling cascades to generate mitogenic and differentiation signals, including the PI 3'-kinase pathway and a pathway regulated by the SHP2 phosphatase (18, 20-22, 38). It has been also demonstrated that activation of the PI 3'-kinase plays an important role in the induction of EPO-mediated cell proliferation (6, 21, 39) and that the catalytic activity of SHP2 plays a significant role in EPO signal transduction (18, 38). The present study implicates Gab proteins as the principal IRS proteins activated by the erythropoietin receptor. Previous studies using the UT-7 multipotential human leukemia cell line have established that IRS-2 is also tyrosine phosphorylated during EPO treatment and associates with the p85 subunit of the PI 3'-kinase, suggesting that this protein is also involved in erythropoietin signaling (30). In our studies, using HCD57 cells and primary human erythroid progenitors, we failed to detect EPO-induced phosphorylation of IRS-1 or IRS-2. The lack of detection of EPO-dependent tyrosine phosphorylation of IRS-2 in HCD57 cells may be due to the heavy baseline tyrosine phosphorylation of the protein. However, only Gab proteins and not IRS-2, were found to associate with the SHP2 phosphatase during treatment of cells with EPO (data not shown), indicating that SHP2 requires Gab proteins and not IRS-2 for its engagement in erythropoietin signaling. These findings are consistent with previous studies performed in UT-7 cells, in which no association between IRS-2 and SHP2 was detected (30). Our data also showed that Gab proteins bind the p85 subunit of the PI 3'-kinase. Previous studies have shown that the p85 subunit of the PI 3'-kinase binds directly to EPO receptor (9). Thus our findings strongly suggest and provide evidence that an alternative pathway for the activation of PI 3'-kinase by EPO involves Gab proteins.
The examination of the expression pattern of Gab proteins in various hematopoietic cells revealed that Gab1 is expressed ubiquitously, whereas expression of Gab2 is selective. Among the cell lines utilized in the study, only the EPO-dependent erythroid cell line HCD57 and TF-1 showed expression of both Gab1 and Gab2. Since Gab1 and Gab2 contain similar structural characteristics (potential phosphorylation sites and their relative positions are conserved in addition to preservation of the pleckstrin homology domain) it would be interesting to determine whether the function of these two proteins are redundant in these cells or they mediate separate biological functions. It is conceivable that in many of the hematopoietic cells, the functional roles of Gab1 and Gab2 are interchangeable. Highly purified primary erythroid progenitors and early uncommitted hematopoietic cells showed expression of only Gab1, indicating that at least in erythroid lineage cells, Gab1 transcripts are continuously expressed throughout differentiation.
Upon EPO stimulation both Gab1 and Gab2 are tyrosine phosphorylated and form complexes with SHP2 and the p85 subunit of the PI 3-kinase. Our data using DA3ER mutants lacking individual tyrosine residues (Y425F and Y367F) within the cytoplasmic domain of the EPO receptor indicate that both tyrosines 425 and 367 are critical for the phosphorylation of Gab2 by EPO. This is in contrast to a previous study in which it was shown that the tyrosine residues of the cytoplasmic domain of gp130 are not necessary for the activation of Gab proteins (33). Also, the same study utilized a gp130 receptor mutant expressed in 293T cells in which the SHP2-binding site of gp130 was mutated to phenylalanine. When gp130 is stimulated in these cells there is no association of SHP2 with Gab1 although Gab1 is phosphorylated. Taken together with our data, the results of these studies indicate the existence of different mechanisms for phosphorylation of Gab proteins based on the ligand activating them. Our results suggest that in EPO signal transduction, at least two tyrosine residues within the cytoplasmic domain of the EPO receptor are needed to phosphorylate Gab proteins. Furthermore, our finding, that Gab2 is not phosphorylated in cells expressing EPO receptors lacking tyrosine 425 raise the possibility that the Gab pathway mediates EPO-dependent mitogenic signals. A previous study (40) has demonstrated that this tyrosine in the cytoplasmic domain of the EPO receptor promotes cell growth in response to EPO, and in cells expressing EPO receptors lacking this tyrosine residue, the mitogenic effects of EPO are diminished. As this residue is also required for engagement of the SHP2 phosphatase (38, 40), it is tempting to hypothesize that Gab proteins are the primary pathway for the activation of SHP2, which mediates mitogenic effects, in EPO signaling.
Although further work is required to precisely define the role of Gab1
and Gab2 in the regulation of the biological effects of erythropoietin,
our data strongly suggest that these proteins, and not the related
IRS-1 and IRS-2, are the principal docking proteins in EPO signaling.
It is likely that, in addition to SHP2 and p85 proteins, Gab1 and Gab2
provide docking sites for other known and unknown proteins activated by
the EPO receptor, which remain to be identified in future studies.
| |
FOOTNOTES |
|---|
* This work was supported the American Cancer Society Illinois Division (to A. W.), National Institutes of Health Grants CA73381 and CA 77816 (to L. C. P.), CA79891 and GM58893 (to T. Y.), grants from the Medical Research Council and the National Cancer Institute of Canada (to G. K.), and a grant from the William B. Keck Foundation, to the Center for Molecular Hematopoiesis at the University of Illinois at Chicago.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence and reprint requests should be addressed: Section of Hematology-Oncology, University of Illinois at Chicago, 900 South Ashland Ave., Chicago, IL 60607. Tel.: 312-413-9280; Fax: 312-413-7963; E-mail: Awickrem@uic.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: EPO, erythropoietin; Gab1, Grb2-associated binder-1; Gab2, Grb2-associated binder-2; IRS, insulin receptor substrate; PI 3'-kinase, phosphatidylinositol 3'-kinase; PAGE, polyacrylamide gel electrophoresis; IL, interleukin; RT-PCR, reverse transcriptase-polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SH2, Src homology domain 2; BFU-E, burst forming unit erythroid; CFU-E, colony forming unit erythroid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Krantz, S. B.
(1991)
Blood
77,
419-434 |
| 2. |
Koury, M. J.,
and Bondurant, M. C.
(1990)
Science
248,
378 |
| 3. | Muta, K., Krantz, S. B., Bondurant, M. C., and Wickrema, A. (1994) J. Clin. Invest 94, 34-43 |
| 4. |
Jacobs-Helber, S. M.,
Wickrema, A.,
Birrder, M. J.,
and Sawyer, S. T.
(1998)
Mol. Cell. Biol
18,
3699-3707 |
| 5. | Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Yi, T., Tang, B., Miura, O., and Ihle, J. N. (1993) Cell 74, 227-236[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Damen, J. E.,
Mui, A. L.,
Cutler, R. L.,
and Krystal, G.
(1993)
Blood
81,
3204-3210 |
| 7. |
Penta, K.,
and Sawyer, S. T.
(1995)
J. Biol. Chem.
270,
31282-31287 |
| 8. | Todokovo, K. M., Sugiyama, E., Nishida, E., and Nakaya, K. (1994) Biochem. Biophys. Res. Commun 203, 1912-1919[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Miura, O.,
Nakamura, N.,
Ihle, J. N.,
and Aoki, N.
(1994)
J. Biol. Chem.
269,
614-620 |
| 10. | Devemy, E., Billat, C., and Haye, B. (1997) Cell Signalling 9, 41-46[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Damen, J. E.,
Liu, L.,
Cutler, R. L.,
and Krystal, G.
(1993)
Blood
82,
2296-2303 |
| 12. |
He, T.-C.,
Jiang, N.,
Zhuang, H.,
and Wojchowski, D. M.
(1995)
J. Biol. Chem.
270,
11055-11061 |
| 13. |
Jacobs-Helber, S. M.,
Penta, K.,
Sun, Z. H.,
Lawson, A.,
and Sawyer, S. T.
(1997)
J. Biol. Chem.
272,
6850-6853 |
| 14. |
Barber, D. L.,
Mason, J. M.,
Fukazawa, T.,
Reedquist, K. A.,
Druker, B. J.,
Band, H.,
and D'Andrea, A. D.
(1997)
Blood
89,
3166-3174 |
| 15. |
Miura, O.,
Miura, Y.,
Nakamura, N.,
Quelle, F. W.,
Witthuhn, B. A.,
Ihle, J. N.,
and Aoki, N.
(1994)
Blood
84,
4135-4141 |
| 16. |
Yi, T.,
Zang, J.,
Miura, O.,
and Ihle, J. N.
(1995)
Blood
85,
87-95 |
| 17. | Klingmuller, U., Lorenz, U., Cantley, L. C., Neel, B. G., and Lodish, H. (1995) Cell 80, 729-738[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Tauchi, T.,
Toyama, K.,
Feng, G. S.,
Broxmeyer, H. E.,
and Krystal, G.
(1996)
Blood
87,
4495-4501 |
| 19. | Chin, H., Saito, T., Arai, A., Yamamoto, K., Kamiyama, R., Miyasaka, N., and Miura, O. (1997) Biochem. Biophys. Res. Commun. 239, 412-417[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
He, T. G.,
Zhuang, H.,
Quelle, D. E.,
and Wojchowski, D. M.
(1993)
Blood
82,
3530-3538 |
| 21. |
Klingmuller, U.,
Wu, H.,
Hsiao, J. G.,
Toker, A.,
Buckworth, B. C.,
Cantley, L. C.,
and Lodish, H. F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3016-3021 |
| 22. |
Joneja, B.,
and Wojchowski, D. M.
(1997)
J. Biol. Chem.
272,
11176-11184 |
| 23. |
Wang, L. M.,
Myers, M. G.,
Sun, X-J.,
Aaranson, S. A.,
White, M. F.,
and Pierce, J. H.
(1993)
Science
261,
1591-1593 |
| 24. | Sun, X-J., Wong, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Pons, S., Wolf, G., Shoelson, S. E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Yin, T.,
Keller, S. R.,
Quelle, F. W.,
Witthuhn, B. A.,
Tsang, M. L.-S.,
Lienhard, G. E.,
Ihle, J. N.,
and Yang, Y.-C.
(1995)
J. Biol. Chem.
270,
20497-20502 |
| 26. |
Johnston, J. A.,
Wang, L.-M.,
Hanson, E. P.,
Sun, X.-J.,
White, M. F.,
Oakes, S. A.,
Pierce, J. H.,
and O'Shea, J. J.
(1995)
J. Biol. Chem.
270,
28527-28530 |
| 27. |
Uddin, S.,
Fish, E. N.,
Sher, D.,
Colamonici, O. R.,
Kellum, M.,
Pitha, P. M.,
White, M. F.,
and Platanias, L. C.
(1997)
Blood
90,
2574-2582 |
| 28. |
Platanias, L. C.,
Uddin, S.,
Yetter, A.,
Sun, X-J.,
and White, M. F.
(1996)
J. Biol. Chem.
271,
278-282 |
| 29. |
Uddin, S.,
Yenush, L.,
Sun, X-J.,
Sweet, M. E.,
White, M. F.,
and Platanias, L. C.
(1995)
J. Biol. Chem.
270,
15938-15941 |
| 30. |
Verdier, F.,
Chretient, S.,
Billat, C.,
Gisselbrecht, S.,
Lacombe, C.,
and Mayeux, P.
(1997)
J. Biol. Chem.
272,
26173-26178 |
| 31. | Holgado-Madruga, M. D. R. E., Mosacatello, D. K., Godwin, A. K., and Wang, A. J. (1996) Nature 319, 560-564 |
| 32. |
Holgado-Madruga, M.,
Moscatello, D. K.,
Emlet, D. R.,
Dieterich, R.,
and Wang, A. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12419-12424 |
| 33. |
Takahashi-Tezuka, M.,
Yoshida, Y.,
Fukada, T.,
Ohtani, T.,
Yamanaka, Y.,
Nishida, K.,
Nakajima, K.,
Hibi, M.,
and Hirano, T.
(1998)
Mol. Cell. Biol.
18,
4109-41117 |
| 34. |
Nishida, K.,
Yoshida, Y.,
Itoh, M.,
Fukada, T.,
Ohtani, T.,
Shirogane, T.,
Astumi, T.,
Takahashi-Tezuka, M.,
Ishihara, K.,
Hibi, M.,
and Hirano, T.
(1999)
Blood
93,
1809-1816 |
| 35. | Gu, H., Pratt, J. C., Burakoff, S. J., and Neel, B. G. (1998) Mol. Cell 2, 729-740[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Wickrema, A.,
Krantz, S. B.,
Winkelmann, J. C.,
and Bondurant, M. C.
(1992)
Blood
80,
1940-1949 |
| 37. | Uddin, S., Fish, E. N., Sher, D. A., Gardziola, C., White, M. F., and Platanias, L. C. (1997) J. Immunol. 158, 2390-2397[Abstract] |
| 38. |
Tauchi, T.,
Feng, G.-S.,
Shen, R.,
Hoatlin, M.,
Baby, G. C., Jr.,
Kabat, D.,
Lu, L.,
and Broxmeyer, H. E.
(1995)
J. Biol. Chem.
270,
5631-5635 |
| 39. | Wu, H., Klingmuller, U., Besmer, P., and Lodish, H. F. (1995) Nature 377, 242-246[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Damen, J. E.,
Cutler, R. L.,
Jiao, H.,
Yi, T.,
and Krystal, J.
(1995)
J. Biol. Chem.
270,
23402-23408 |
This article has been cited by other articles:
![]() |
J.-A. Kang, Y. Zhou, T. L. Weis, H. Liu, J. Ulaszek, N. Satgurunathan, L. Zhou, K. van Besien, J. Crispino, A. Verma, et al. Osteopontin Regulates Actin Cytoskeleton and Contributes to Cell Proliferation in Primary Erythroblasts J. Biol. Chem., March 14, 2008; 283(11): 6997 - 7006. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Navas, M. Mohindru, M. Estes, J. Y. Ma, L. Sokol, P. Pahanish, S. Parmar, E. Haghnazari, L. Zhou, R. Collins, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors Blood, December 15, 2006; 108(13): 4170 - 4177. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Menon, J. Fang, and D. M. Wojchowski Core erythropoietin receptor signals for late erythroblast development Blood, April 1, 2006; 107(7): 2662 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Katsoulidis, Y. Li, P. Yoon, A. Sassano, J. Altman, P. Kannan-Thulasiraman, L. Balasubramanian, S. Parmar, J. Varga, M. S. Tallman, et al. Role of the p38 Mitogen-Activated Protein Kinase Pathway in Cytokine-Mediated Hematopoietic Suppression in Myelodysplastic Syndromes Cancer Res., October 1, 2005; 65(19): 9029 - 9037. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Montoye, I. Lemmens, D. Catteeuw, S. Eyckerman, and J. Tavernier A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach Blood, June 1, 2005; 105(11): 4264 - 4271. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. van den Akker, T. van Dijk, M. Parren-van Amelsvoort, K. S. Grossmann, U. Schaeper, K. Toney-Earley, S. E. Waltz, B. Lowenberg, and M. von Lindern Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors Blood, June 15, 2004; 103(12): 4457 - 4465. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Podar, G. Mostoslavsky, M. Sattler, Y.-T. Tai, T. Hayashi, L. P. Catley, T. Hideshima, R. C. Mulligan, D. Chauhan, and K. C. Anderson Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells J. Biol. Chem., May 14, 2004; 279(20): 21658 - 21665. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uddin, J. Ah-Kang, J. Ulaszek, D. Mahmud, and A. Wickrema Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells PNAS, January 6, 2004; 101(1): 147 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bouscary, F. Pene, Y.-E. Claessens, O. Muller, S. Chretien, M. Fontenay-Roupie, S. Gisselbrecht, P. Mayeux, and C. Lacombe Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation Blood, May 1, 2003; 101(9): 3436 - 3443. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Hoffman, A. Wickrema, O. Potapova, M. Milanick, and D. R. Yingst Na pump isoforms in human erythroid progenitor cells and mature erythrocytes PNAS, October 29, 2002; 99(22): 14572 - 14577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gogg and U. Smith Epidermal Growth Factor and Transforming Growth Factor alpha Mimic the Effects of Insulin in Human Fat Cells and Augment Downstream Signaling in Insulin Resistance J. Biol. Chem., September 20, 2002; 277(39): 36045 - 36051. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Saito, Y. Hojo, T. Tanimoto, J.-i. Abe, and B. C. Berk Protein Kinase C-alpha and Protein Kinase C-epsilon Are Required for Grb2-associated Binder-1 Tyrosine Phosphorylation in Response to Platelet-derived Growth Factor J. Biol. Chem., June 21, 2002; 277(26): 23216 - 23222. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Verma, D. K. Deb, A. Sassano, S. Kambhampati, A. Wickrema, S. Uddin, M. Mohindru, K. Van Besien, and L. C. Platanias Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia J. Immunol., June 15, 2002; 168(12): 5984 - 5988. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Lock, C. R. Maroun, M. A. Naujokas, and M. Park Distinct Recruitment and Function of Gab1 and Gab2 in Met Receptor-mediated Epithelial Morphogenesis Mol. Biol. Cell, June 1, 2002; 13(6): 2132 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Itoh, M. Itoh, K. Nishida, S. Yamasaki, Y. Yoshida, M. Narimatsu, S. J. Park, M. Hibi, K. Ishihara, and T. Hirano Adapter Molecule Grb2-Associated Binder 1 Is Specifically Expressed in Marginal Zone B Cells and Negatively Regulates Thymus-Independent Antigen-2 Responses J. Immunol., May 15, 2002; 168(10): 5110 - 5116. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-M. Yu, T. S. Hawley, R. G. Hawley, and C.-K. Qu Role of the docking protein Gab2 in beta 1-integrin signaling pathway-mediated hematopoietic cell adhesion and migration Blood, April 1, 2002; 99(7): 2351 - 2359. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Verma, D. K. Deb, A. Sassano, S. Uddin, J. Varga, A. Wickrema, and L. C. Platanias Activation of the p38 Mitogen-activated Protein Kinase Mediates the Suppressive Effects of Type I Interferons and Transforming Growth Factor-beta on Normal Hematopoiesis J. Biol. Chem., March 1, 2002; 277(10): 7726 - 7735. [Abstract] [Full Text] [PDF] |
||||